# PackGene Biotech, Inc.

> PackGene Biotech is a Houston-based contract research, development and manufacturing company supplying AAV vectors, plasmid DNA, lentiviral vectors, and mRNA/LNP services to academic laboratories and drug developers. Its proprietary production platforms, vector-design tools and analytical testing connect early research with clinical manufacturing, with service and manufacturing operations in the United States and China.

- **Founded:** 2014
- **Headquarters:** Houston, United States
- **Founders:** Huapeng Li (Founder; identified as chairman and general manager in public company databases)
- **Products:** π-Alpha 293 AAV High-yield Production Platform, π-Omega Plasmid DNA High-yield Platform, π-Icosa AAV Capsid Screening Platform, piVector Designer, Express Gene-to-AAV Service
- **Notable:** Developed proprietary AAV production, plasmid-production and capsid-screening platforms., Broke ground on a 25,000-square-foot Houston biomanufacturing expansion in February 2023., Company reported more than 50 GMP clinical batches on its manufacturing service page.

## Products & services

- **π-Alpha 293 AAV High-yield Production Platform** — Proprietary suspension cells, engineered plasmids and process optimization for AAV production. Company material reports 3-8-fold improvement from foundational changes and up to 10-fold overall yield improvement; its August 2026 announcement describes π-Alpha 2.0 with a dual-plasmid system. These are company claims, not guaranteed results.
- **π-Omega Plasmid DNA High-yield Platform** — Plasmid-backbone modifications and purification processes; the company reports over threefold yield improvement, up to 200L production and up to 100 grams per batch.
- **π-Icosa AAV Capsid Screening Platform** — AAV capsid screening for tissue targeting and infectivity; the company describes a mutant library exceeding one billion variants.
- **piVector Designer** — Free online DNA construct design tool with verified AAV and lentivirus backbones, sequence elements, tracking, reordering and links to synthesis and packaging.
- **Express Gene-to-AAV Service** — Gene synthesis, plasmid construction, selected-serotype AAV packaging and QC reporting; advertised research turnaround as fast as four weeks, depending on project.
- **GMP AAV Manufacturing** — Process development, scale-up, clinical-grade vector production, analytical testing, fill and finish, batch release and regulatory documentation support.
- **GMP Plasmid DNA Manufacturing** — Plasmid process development and manufacturing for viral vectors and mRNA templates.
- **AAV Analytical Development and QC** — Assay development, optimization and validation for identity, purity, genome integrity, potency, residual contaminants and safety.
- **mRNA and LNP Services** — Custom mRNA, formulation and lipid nanoparticle services; 2023 Kudo collaboration connects PackGene plasmid and cell-banking work to partner mRNA production, encapsulation and fill-finish.
- **Lentivirus Packaging and Vector Construction** — Research lentiviral vector packaging, plasmid design and construction, and gene-to-lentivirus services.
- **Off-the-shelf Research Products** — Ready-made AAV, plasmid and mRNA/LNP products for laboratory work.

## Achievements

- Developed proprietary AAV production, plasmid-production and capsid-screening platforms.
- Broke ground on a 25,000-square-foot Houston biomanufacturing expansion in February 2023.
- Company reported more than 50 GMP clinical batches on its manufacturing service page.
- Company reported over 2,000 pharmaceutical and research organizations served across more than 30 countries and regions in August 2026.
- Announced receipt of Frost & Sullivan’s Global Gene Therapy CRDMO Technology Innovation Leadership Award in August 2026.

## Latest updates

- **2026-01** — Company described a bioRxiv preprint exploring engineered AAV capsids, expression regulation and intramuscular delivery in a lymphoma model; preclinical research, not demonstrated clinical efficacy.
- **2026-06** — Company news archive announced 25+ IND projects and 30+ investigator-initiated trial projects delivered; counts are company-reported.
- **2026-08** — Company announced Frost & Sullivan technology innovation award and described π-Alpha 2.0 dual-plasmid production technology.

## Links

- Website: https://www.packgene.com/
- LinkedIn: https://www.linkedin.com/company/packgene-biotech-inc/
- Twitter/X: https://twitter.com/PackGeneBiotech
- YouTube: https://www.youtube.com/channel/UCyTzi6YHM2C_Ryhjfn1rTQw

---

Profile page: https://yespress.io/packgene-biotech-inc
Published by YesPress — https://yespress.io
Last updated: 2026-10-04